Xeno-Free Reprogramming of Peripheral Blood Mononuclear Erythroblasts on Laminin-521.
Cell Differentiation
Cell Proliferation
Cellular Reprogramming
/ drug effects
Clone Cells
Cryopreservation
Erythrocytes
/ cytology
Extracellular Matrix
/ metabolism
Humans
Induced Pluripotent Stem Cells
/ cytology
Laminin
/ pharmacology
Leukocytes, Mononuclear
/ cytology
Plasmids
/ metabolism
RNA, Viral
/ metabolism
Sendai virus
/ genetics
Serum
Sendai viral reprogramming
episomal reprogramming
human induced pluripotent stem cells (hiPSCs)
reprogramming
Journal
Current protocols in stem cell biology
ISSN: 1938-8969
Titre abrégé: Curr Protoc Stem Cell Biol
Pays: United States
ID NLM: 101470226
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
entrez:
25
1
2020
pubmed:
25
1
2020
medline:
11
6
2021
Statut:
ppublish
Résumé
Translating human induced pluripotent stem cell (hiPSC)-derived cells and tissues into the clinic requires streamlined and reliable production of clinical-grade hiPSCs. This article describes an entirely animal component-free procedure for the reliable derivation of stable hiPSC lines from donor peripheral blood mononuclear cells (PBMCs) using only autologous patient materials and xeno-free reagents. PBMCs are isolated from a whole blood donation, from which a small amount of patient serum is also generated. The PBMCs are then expanded prior to reprogramming in an animal component-free erythroblast growth medium supplemented with autologous patient serum, thereby eliminating the need for animal serum. After expansion, the erythroblasts are reprogrammed using either cGMP-grade Sendai viral particles (CytoTune™ 2.1 kit) or episomally replicating reprogramming plasmids (Epi5™ kit), both commercially available. Expansion of emerging hiPSCs on a recombinant cGMP-grade human laminin substrate is compatible with a number of xeno-free or chemically defined media (some available as cGMP-grade reagents), such as E8, Nutristem, Stemfit, or mTeSR Plus. hiPSC lines derived using this method display expression of expected surface markers and transcription factors, loss of the reprogramming agent-derived nucleic acids, genetic stability, and the ability to robustly differentiate in vitro to multiple lineages. © 2020 by John Wiley & Sons, Inc. Basic Protocol 1: Isolating peripheral blood mononuclear cells using CPT tubes Support Protocol 1: Removal of clotting factors to produce serum from autologous plasma collected in Basic Protocol 1 Basic Protocol 2: PBMC expansion in an animal-free erythroblast expansion medium containing autologous serum Basic Protocol 3: Reprogramming of expanded PBMCs with Sendai viral reprogramming particles Alternate Protocol: Reprogramming of expanded PBMCs with episomal plasmids Basic Protocol 4: Picking, expanding, and cryopreserving hiPSC clones Support Protocol 2: Testing Sendai virus kit-reprogrammed hiPSC for absence of Sendai viral RNA Support Protocol 3: Testing Epi5 kit-reprogrammed hiPSC for absence of episomal plasmid DNA Support Protocol 4: Assessing the undifferentiated state of human pluripotent stem cell cultures by multi-color immunofluorescent staining and confocal imaging Support Protocol 5: Coating plates with extracellular matrices to support hiPSC attachment and expansion.
Identifiants
pubmed: 31977148
doi: 10.1002/cpsc.103
pmc: PMC7176073
mid: NIHMS1578341
doi:
Substances chimiques
Laminin
0
RNA, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e103Subventions
Organisme : NIDDK NIH HHS
ID : U54 DK110805
Pays : United States
Informations de copyright
© 2020 John Wiley & Sons, Inc.
Références
Curr Protoc Stem Cell Biol. 2018 May;45(1):e48
pubmed: 30040234
Nature. 2017 May 11;545(7653):229-233
pubmed: 28445466
Adv Biochem Eng Biotechnol. 2018;163:1-21
pubmed: 29075799
Nat Biotechnol. 2006 Feb;24(2):185-7
pubmed: 16388305
Sci Rep. 2012;2:213
pubmed: 22355727
Cell. 2011 Feb 4;144(3):439-52
pubmed: 21295703
Biochemistry. 1986 Jan 28;25(2):312-8
pubmed: 2937447
Stem Cell Res Ther. 2018 Nov 8;9(1):307
pubmed: 30409192
Stem Cells. 2013 Mar;31(3):458-66
pubmed: 23193063
Cell Stem Cell. 2008 Dec 4;3(6):607-9
pubmed: 19041777
Sci Rep. 2014 Jan 08;4:3594
pubmed: 24399248
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Nat Biotechnol. 2001 Oct;19(10):971-4
pubmed: 11581665
Curr Protoc Stem Cell Biol. 2016 Aug 17;38:4A.9.1-4A.9.10
pubmed: 27532818
Regen Med. 2015 Nov;10(8):939-58
pubmed: 26345388
Nat Biotechnol. 2005 Jan;23(1):19-20
pubmed: 15637610
Stem Cell Rev Rep. 2016 Aug;12(4):394-420
pubmed: 27283945
Nat Methods. 2011 May;8(5):424-9
pubmed: 21478862
Curr Protoc Stem Cell Biol. 2007 Sep;Chapter 1:Unit 1C.2
pubmed: 18785163
Nat Biotechnol. 2015 Jan;33(1):58-63
pubmed: 25437882
Curr Protoc Stem Cell Biol. 2011 Dec;Chapter 1:Unit 1C.12
pubmed: 22135082
Curr Protoc Stem Cell Biol. 2015 Feb 02;32:1C.18.1-1C.18.8
pubmed: 25640816
Sci Rep. 2017 Jan 30;7:41165
pubmed: 28134277
Cloning Stem Cells. 2008 Mar;10(1):107-18
pubmed: 18241122
Stem Cell Reports. 2015 Oct 13;5(4):647-59
pubmed: 26411904
Nat Biotechnol. 2007 Jun;25(6):681-6
pubmed: 17529971
Nat Methods. 2011 May;8(5):409-12
pubmed: 21460823
Nat Protoc. 2014 Oct;9(10):2354-68
pubmed: 25211513
N Engl J Med. 2004 Mar 25;350(13):1353-6
pubmed: 14999088
Reprod Biol Endocrinol. 2015 Feb 22;13:9
pubmed: 25890180
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14234-9
pubmed: 21821793
PLoS One. 2015 Feb 25;10(2):e0118307
pubmed: 25714340
Sci Transl Med. 2019 Mar 6;11(482):
pubmed: 30842315
Nat Biotechnol. 2004 Apr;22(4):381-2; author reply 382
pubmed: 15060545
Nature. 2017 May 25;545(7655):432-438
pubmed: 28514439
Sci Rep. 2016 Jul 29;6:30742
pubmed: 27471043
J Clin Invest. 2015 Jul 1;125(7):2551-7
pubmed: 26132109
Curr Protoc Hum Genet. 2015 Oct 06;87:21.2.1-21.2.21
pubmed: 26439714